1[1]Regar E,Serruys PW,Bode C,et al.Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent(RAVEL):sirolimus-eluting stents inhibit restenosis irrespective of the vessel size[J].Circulation,2002,106(15):1949-1956.
2[2]Moses JW,Leon MB,Popma JJ,et al.Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery[J].N Engl J Med,2003,349(14):1315-1323.
3[3]Schofer J,Schluter M,Gershlick AH,et al.Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries:double-blind,randomized controlled trial(E-SIRIUS)[J].Lancet,2003,362(4):1093-1099.
4[4]Schampaert E,Cohen EA,Schluter M,et al.The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries(C-SIRIUS)[J].J Am Coll Cardiol,2004,43(6):1110-1115.
5[5]Holmes DR,Leon MB,Moses JW,et al.Analysis of 1-year clinical outcomes in the SIRIUS trial.A randomized trial of a sirolimus-eluting stent versus a standared stent in patients at high risk for coronary restenosis[J].Circulation,2004,109(5):634-640.
8[8]Dibra A,Kastrati A,Mehilli J,et al.Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients[J].N Engl J Med,2005,353(7):663-670.
9[9]Morice MC,Serruys PW,Colombo A,et al.Eight-month outcome of the REALITY study:a prospective,randomized,multi-center head-to -head comparison of the sirolimuseluting stent(Cypher)and the paclitaxel-eluting stent(Taxus)[C].Presented at the 2005 Annual Scientific Session of the American College of Cardiology,Orlando,Fla.,March 6-9,2005.
10[10]Katritsis DG,Karvouni E,Ioannidis JP.Meta-analysis comparing drug-eluting stents with bare metal stents[J].Am J Cardiol,2005,95(5):640-643.
1Finn A V, Kolodgie F D, Harnek J, et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus-or paclitaxel-eluting stents[ J]. Circulation,2005,112(2) :270-278.
2Virmani R, Guaglimui G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent : should we be cautious? [ J]. Circulation ,2004,109 (6) :701-705.
3Wieneke H, Dirsch O, Sawitowski T, et al. Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits [J].Catheter. Cardiovasc. Interv. ,2003,60 (3) :399-407.
4Serruys P W, Sianos G, Abizaid A, et al. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform : the paclitaxel in-stent controlled elution study (PISCES) [ J ]. J. Am. Coll. Cardiol,2005,46 (2) :253-260.
5Wessely R, Hausleiter J, Michaelis C, et al. Inhibition of neointima formation by a novel drug-eluting stent system that alows for dose-adjustable, multiple, and on-site stent coating[ J].Arter. Thromb. Vasc. Biol,2005,25(4) :748-753.
